Rheumatology Advance Access originally published online on November 23, 2004
Rheumatology 2005 44(3):274-279; doi:10.1093/rheumatology/keh487
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology Vol. 44 No. 3 © British Society for Rheumatology 2004; all rights reserved
REVIEW |
Localized scleroderma is an autoimmune disorder
Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Correspondence to: K. Takehara, 13-1 Takara-machi, Kanazawa, 920-8641, Japan. E-mail: takehara{at}med.kanazawa-u.ac.jp
Objectives. There have been many studies suggesting that localized scleroderma has a strong autoimmune background, although the lesions are usually limited to the skin and subcutaneous tissue. Here we summarize previous data on the autoimmunity of localized scleroderma, mostly published in the last two decades, because there has not been a review paper summarizing autoimmunity in this disorder.
Methods. We classified the previous reports into three categories: antinuclear antibodies; cytokine and soluble receptors; and cell adhesion molecules and cell surface molecules. In each category, we introduce the important investigations.
Results. High frequencies of antinuclear antibodies, detected by the indirect immunofluorescence method using cultured cells, are confirmed by many groups. The major autoantigens have been revealed to be histones. Recently, anti-topoisomerase II 
antibody has been found to be detected highly frequently in localized scleroderma, while anti-topoisomerase I antibody, which is highly specific for systemic sclerosis, has not been detected in any case of localized scleroderma. In other studies, elevated serum cytokines and cell adhesion molecules suggest the immunoactivation of localized scleroderma.
Conclusions. Many previous studies conclude that localized scleroderma involves autoimmune abnormalities and is one of the organ-specific autoimmune disorders targeting mainly skin, although the types of autoimmune abnormality are different from systemic sclerosis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Badea, M. Taylor, A. Rosenberg, and M. Foldvari Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis Rheumatology, March 1, 2009; 48(3): 213 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Neustadter, F. Samarin, K. R. Carlson, and M. Girardi Extracorporeal Photochemotherapy for Generalized Deep Morphea Arch Dermatol, February 1, 2009; 145(2): 127 - 130. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Horger, G. Fierlbeck, J. Kuemmerle-Deschner, N. Tzaribachev, M. Wehrmann, C. D. Claussen, and J. Fritz MRI Findings in Deep and Generalized Morphea (Localized Scleroderma) Am. J. Roentgenol., January 1, 2008; 190(1): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, S. Vodanovic-Jankovic, B. Johnson, M. Keller, R. Komorowski, and W. R. Drobyski Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease Blood, November 15, 2007; 110(10): 3804 - 3813. [Abstract] [Full Text] [PDF]
|
|